Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
eqs_en 
0 04.04.22
Kaufman & Broad SA: AVAILABILITY OF THE 2021 UNIVERSAL REGISTRATION DOCUMENT
Kaufman & Broad SA: AVAILABILITY OF THE 2021 UNIVERSAL REGISTRATION DOCUMENT
Kaufman & Broad SA: AVAILABILITY OF THE 2021 UNIVERSAL REGISTRATION DOCUMENT
eqs_en 
0 31.03.22
Joshua Schafer Appointed as Interim Chairman of Pharnext Board of Directors
Joshua Schafer Appointed as Interim Chairman of Pharnext Board of Directors
Joshua Schafer Appointed as Interim Chairman of Pharnext Board of Directors
eqs_en 
0 30.03.22
DGAP-News: Abivax reports 2021 financial results and operations update
DGAP-News: Abivax reports 2021 financial results and operations update
DGAP-News: Abivax reports 2021 financial results and operations update
eqs_en 
0 16.03.22
DGAP-News: Abivax veröffentlicht Finanzergebnisse für das Jahr 2021 und gibt Update zur Unternehmensentwicklung
DGAP-News: Abivax veröffentlicht Finanzergebnisse für das Jahr 2021 und gibt Update zur Unternehmensentwicklung
DGAP-News: Abivax veröffentlicht Finanzergebnisse für das Jahr 2021 und gibt Update zur Unternehmensentwicklung
eqs_de 
0 16.03.22
ROCTOOL: Yearly results 2021 - Strong acceleration of activity: +27%
ROCTOOL: Yearly results 2021 - Strong acceleration of activity: +27%
ROCTOOL: Yearly results 2021 - Strong acceleration of activity: +27%
eqs_en 
0 16.03.22
RUBIS: 2021 annual results: increase in earnings and proposed dividend - acceleration in renewable energy
RUBIS: 2021 annual results: increase in earnings and proposed dividend - acceleration in renewable energy
RUBIS: 2021 annual results: increase in earnings and proposed dividend - acceleration in renewable energy
eqs_en 
0 10.03.22
DGAP-News: Abivax reports promising ABX464 phase 2a one-year maintenance results in rheumatoid arthritis
DGAP-News: Abivax reports promising ABX464 phase 2a one-year maintenance results in rheumatoid arthritis
DGAP-News: Abivax reports promising ABX464 phase 2a one-year maintenance results in rheumatoid arthritis
eqs_en 
0 10.03.22
DGAP-News: Abivax gibt vielversprechende Einjahres-Langzeitdaten aus seiner Phase-2a-Studie mit ABX464 zur Behandlung von rheumatoider Arthritis bekannt
DGAP-News: Abivax gibt vielversprechende Einjahres-Langzeitdaten aus seiner Phase-2a-Studie mit ABX464 zur Behandlung von rheumatoider Arthritis bekannt
DGAP-News: Abivax gibt vielversprechende Einjahres-Langzeitdaten aus seiner Phase-2a-Studie mit ABX464 zur Behandlung von rheumatoider Arthritis bekannt
eqs_de 
0 10.03.22
SPAC: Notice of Combined General Meeting to be held on April 8, 2022 - Launch of a new strategic project - Proposed acquisition of MyHotelMatch
SPAC: Notice of Combined General Meeting to be held on April 8, 2022 - Launch of a new strategic project - Proposed acquisition of MyHotelMatch
SPAC: Notice of Combined General Meeting to be held on April 8, 2022 - Launch of a new strategic project - Proposed acquisition of MyHotelMatch
eqs_en 
0 07.03.22
SPAC: Notice of Combined General Meeting to be held on April 8, 2022 - Launch of a new strategic project - Proposed acquisition of MyHotelMatch
SPAC: Notice of Combined General Meeting to be held on April 8, 2022 - Launch of a new strategic project - Proposed acquisition of MyHotelMatch
SPAC: Notice of Combined General Meeting to be held on April 8, 2022 - Launch of a new strategic project - Proposed acquisition of MyHotelMatch
eqs_en 
0 07.03.22
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
eqs_en 
0 02.03.22
REALITES: Sharp increase in turnover in 2021: €285.7m, representing a growth of around 40%
REALITES: Sharp increase in turnover in 2021: €285.7m, representing a growth of around 40%
REALITES: Sharp increase in turnover in 2021: €285.7m, representing a growth of around 40%
eqs_en 
0 01.03.22
Freelance.com: Persistently robust growth in France and internationally
Freelance.com: Persistently robust growth in France and internationally
Freelance.com: Persistently robust growth in France and internationally
eqs_en 
0 01.03.22
BILENDI: Bilendi surpasses 2023 revenue target 2 years ahead of schedule and changes dimension
BILENDI: Bilendi surpasses 2023 revenue target 2 years ahead of schedule and changes dimension
BILENDI: Bilendi surpasses 2023 revenue target 2 years ahead of schedule and changes dimension
eqs_en 
0 23.02.22
PATRIMOINE ET COMMERCE: 2021 ANNUAL RESULTS
PATRIMOINE ET COMMERCE: 2021 ANNUAL RESULTS
PATRIMOINE ET COMMERCE: 2021 ANNUAL RESULTS
eqs_en 
0 23.02.22
SPAC: Strategic Turnaround - Entry into Exclusive Negotiations to Acquire an Artificial Intelligence (AI) Hotel Reservation Platform
SPAC: Strategic Turnaround - Entry into Exclusive Negotiations to Acquire an Artificial Intelligence (AI) Hotel Reservation Platform
SPAC: Strategic Turnaround - Entry into Exclusive Negotiations to Acquire an Artificial Intelligence (AI) Hotel Reservation Platform
eqs_en 
0 21.02.22
Pharnext appoints Valérie Worrall as Chief Financial Officer
Pharnext appoints Valérie Worrall as Chief Financial Officer
Pharnext appoints Valérie Worrall as Chief Financial Officer
eqs_en 
0 15.02.22
RUBIS: Q4 2021: Volumes growth: +5% - Robust unit margins
RUBIS: Q4 2021: Volumes growth: +5% - Robust unit margins
RUBIS: Q4 2021: Volumes growth: +5% - Robust unit margins
eqs_en 
0 10.02.22
RUBIS: Capital increase reserved for Group's employees
RUBIS: Capital increase reserved for Group's employees
RUBIS: Capital increase reserved for Group's employees
eqs_en 
0 09.02.22
DGAP-News: Abivax veranstaltet am 17. Februar 2022 ein Satellite Symposium auf dem 17. Kongress der European Crohn's and Colitis Organisation (ECCO)
DGAP-News: Abivax veranstaltet am 17. Februar 2022 ein Satellite Symposium auf dem 17. Kongress der European Crohn's and Colitis Organisation (ECCO)
DGAP-News: Abivax veranstaltet am 17. Februar 2022 ein Satellite Symposium auf dem 17. Kongress der European Crohn's and Colitis Organisation (ECCO)
eqs_de 
0 08.02.22
DGAP-News: Abivax to host Satellite Symposium at the 17th Congress of ECCO on Feb. 17, 2022
DGAP-News: Abivax to host Satellite Symposium at the 17th Congress of ECCO on Feb. 17, 2022
DGAP-News: Abivax to host Satellite Symposium at the 17th Congress of ECCO on Feb. 17, 2022
eqs_en 
0 08.02.22
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
eqs_en 
0 04.02.22
RUBIS: Information relating to the total number of voting rights and shares as of 01/31/2022
RUBIS: Information relating to the total number of voting rights and shares as of 01/31/2022
RUBIS: Information relating to the total number of voting rights and shares as of 01/31/2022
eqs_en 
0 02.02.22
Kaufman & Broad SA: 2021 ANNUAL RESULTS
Kaufman & Broad SA: 2021 ANNUAL RESULTS
Kaufman & Broad SA: 2021 ANNUAL RESULTS
eqs_en 
0 27.01.22